New Major Pharma Client for Schizophrenia Trials

RNS Number : 8378X
Cambridge Cognition Holdings PLC
10 January 2022
 

 

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition announces new major pharma client for schizophrenia clinical trials

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has been awarded contracts for two clinical trials by a top 20 pharmaceutical company to assess the pro-cognitive effects of a new drug in schizophrenia. Together the contracts are worth £700,000 over two years. This is the second pharmaceutical client to award Cambridge Cognition major contracts for cognitive assessments for schizophrenia in the last year1. Approximately 30 clinical trials on new drugs for schizophrenia run every year2, demonstrating the potential for further sales in this therapeutic area.

 

Cambridge Cognition offers cognitive assessments with the sensitivity to measure the distinct cognitive processes impaired in schizophrenia, including memory, attention and executive function. Between September 2020 and December 2021, the Company was contracted for six pivotal trials for another client's new schizophrenia drug1, earning Cambridge Cognition a reputation in the field for delivering highly sensitive cognitive assessments. Now, this new client, a top 20 pharmaceutical company has contracted Cambridge Cognition to determine the efficacy of its new drug for improving cognition in patients with schizophrenia and another indication. Cambridge Cognition will provide its proprietary cognitive assessments (CANTABTM), its electronic questionnaires and scales platform (eCOA), and specialist, study management services.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"It is excellent news that we have secured another top 20 pharmaceutical company as a new client and that we are conducting more clinical trials for patients with schizophrenia, which is a therapeutic area we are targeting for growth.  We are pleased with this client win which continues the very positive momentum in the business and further improves our revenue visibility."

 

1.  Announced by the Company on 1 September 2020, 30 March 2021, 26 October 2021 and 9 December 2021

2.  TrialTrove search of industry sponsored PhII - IV Schizophrenia Trials 2011 - 2021

 

For further information, contact:

 

Cambridge Cognition Holdings Plc

Matthew Stork, Chief Executive Officer

Sally Jennings, Head of Marketing & Communications

Tel: 012 2381 0700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTUPUUWGUPPGMM
UK 100

Latest directors dealings